Healthcare News
Medicare GLP-1 Bridge: what weight loss clinics and primary care practices should know
Since 1 July 2026, Medicare has had a temporary program, the Medicare GLP-1 Bridge, that covers certain obesity GLP-1 drugs for eligible people. Patients are asking about it. This guide explains who qualifies, what prescribers must do, what comes next, and how to talk about it without making claims you cannot support.
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a temporary Medicare program that began on 1 July 2026 and covers certain obesity GLP-1 drugs for eligible people with Part D, for a $50 copay per one-month supply. It works outside the usual Part D benefit. A longer-term demonstration, the BALANCE Model, is planned to follow in 2027, and its details are still uncertain.
Not medical or legal advice
This is a summary of Medicare.gov and KFF pages. Program details, drug lists and dates can change. Always confirm on Medicare.gov before advising patients or publishing ads.
Who is eligible?
According to Medicare.gov, a patient must have Part D coverage, be 18 or older, and meet one of these:
- a BMI of 35 or more; or
- a BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or higher; or
- a BMI of 27 or more with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
People are not eligible if they already get a GLP-1 covered by Part D, or if they have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease. Part D may cover a GLP-1 for those conditions instead.
Drugs and cost
- Covered drugs listed by Medicare: Foundayo (tablet), Wegovy (injection or tablet) and Zepbound (KwikPen only, not single-dose vials or pens).
- Copay: $50 per one-month supply. It does not count toward the Part D deductible or out-of-pocket limit.
- Compounded drugs: compounded GLP-1s are not FDA-approved, and are not part of this program.
What prescribers must do
- Send the prescription to the patient's pharmacy.
- Complete prior authorization when requested. KFF reports that requests go through a central processor managed by CMS.
- Certify that the drug is used as part of a lifestyle program that focuses on diet and exercise.
What comes next
KFF reports that the BALANCE Model, a multi-year demonstration, is planned to begin in 2027, with voluntary participation by Part D plans. Bridge patients may need to change plans during 2027 open enrollment. KFF also notes the $50 copay may be a barrier for patients with lower incomes.
What weight loss and primary care clinics can do
- Prepare a short patient FAQ that links to Medicare.gov, rather than quoting coverage from memory.
- Give your front desk a script for eligibility questions and for booking a consultation.
- Reply to enquiries fast. Interest spikes when coverage news breaks, and the first clinic to answer often books the visit.
- Follow ad rules. Avoid guarantees, keep health details out of ad tracking and use the safer wording in our GLP-1 clinic marketing guide.
- Measure what matters. Track cost per booked and attended consultation. See our approach for weight loss clinics and the Medi-Weightloss case study.
Frequently asked questions
What is the Medicare GLP-1 Bridge?
A temporary Medicare program that began on 1 July 2026 and covers certain GLP-1 drugs for obesity, outside the regular Part D benefit, for eligible people. A longer-term demonstration called the BALANCE Model is planned for 2027.
How much does a patient pay?
Medicare.gov says $50 per one-month supply. It does not count toward the Part D deductible or out-of-pocket limit, and Extra Help cannot lower it.
Which drugs are covered?
Medicare.gov lists Foundayo (tablet), Wegovy (injection or tablet) and Zepbound (KwikPen only). The list can change, so check the current page.
What must a prescriber do?
Send the prescription to the pharmacy, complete prior authorization when requested, and certify that the drug is used as part of a lifestyle program that focuses on diet and exercise.
Can a clinic advertise that Medicare covers weight loss drugs?
Be careful. Coverage depends on eligibility, and people already covered for a GLP-1 under Part D for another reason are not eligible for the Bridge. Keep ads factual, avoid guarantees, and have a compliance advisor review them.
This article is general information. It is not medical, legal or billing advice. Published 20 November 2026.
Sources
See where your clinic can grow
Your free 30-minute growth audit is a real review of your clinic: ads, tracking, booking page, follow-up and show-ups. You leave with a clear list of what to fix first. No obligation, and no patient information needed.
Get a free growth auditFree, no obligationReply within one business dayWorks inside your current CRM